Kilitch Drugs (India) Ltd
Kilitch Drugs (India) Ltd is a speciality pharmaceutical company engaged in manufacturing and trading of pharmaceutical products in domestic and international markets.[1]
- Market Cap ₹ 625 Cr.
- Current Price ₹ 389
- High / Low ₹ 470 / 138
- Stock P/E 50.3
- Book Value ₹ 104
- Dividend Yield 0.00 %
- ROCE 9.88 %
- ROE 5.40 %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 3.74 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 4.03% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2010 | Mar 2011 | Mar 2012 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
143 | 146 | 108 | 19 | 21 | 27 | 51 | 82 | 53 | 68 | 114 | 140 | 155 | |
119 | 124 | 95 | 21 | 25 | 28 | 45 | 75 | 53 | 63 | 104 | 122 | 132 | |
Operating Profit | 23 | 22 | 13 | -2 | -4 | -1 | 6 | 7 | 0 | 5 | 10 | 18 | 23 |
OPM % | 16% | 15% | 12% | -9% | -19% | -2% | 11% | 9% | 1% | 8% | 9% | 13% | 15% |
0 | 0 | 92 | 3 | 2 | 1 | 3 | 4 | 4 | 3 | 3 | 3 | 5 | |
Interest | 5 | 4 | 3 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 5 | 6 |
Depreciation | 6 | 6 | 5 | 2 | 10 | 10 | 2 | 2 | 2 | 2 | 2 | 4 | 3 |
Profit before tax | 13 | 13 | 97 | -1 | -12 | -9 | 6 | 9 | 2 | 5 | 10 | 12 | 19 |
Tax % | 22% | 20% | 22% | 70% | 4% | 5% | 16% | 55% | 48% | 27% | 35% | 31% | |
10 | 10 | 76 | -0 | -11 | -9 | 5 | 4 | 1 | 4 | 6 | 8 | 13 | |
EPS in Rs | 7.75 | 7.93 | 57.67 | -0.22 | -8.46 | -6.72 | 3.75 | 2.49 | 0.54 | 2.43 | 4.73 | 6.71 | 9.20 |
Dividend Payout % | 13% | 13% | 52% | 0% | 0% | 0% | 13% | 20% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 22% |
3 Years: | 38% |
TTM: | 19% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 12% |
3 Years: | 237% |
TTM: | 62% |
Stock Price CAGR | |
---|---|
10 Years: | 35% |
5 Years: | 15% |
3 Years: | 68% |
1 Year: | 177% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 3% |
3 Years: | 4% |
Last Year: | 5% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2010 | Mar 2011 | Mar 2012 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 13 | 13 | 13 | 13 | 13 | 13 | 14 | 15 | 15 | 15 | 16 | 16 | 16 |
Reserves | 62 | 71 | 101 | 107 | 95 | 88 | 98 | 106 | 103 | 112 | 121 | 131 | 151 |
43 | 16 | 9 | 0 | 0 | 1 | 1 | 9 | 13 | 15 | 20 | 22 | 29 | |
21 | 53 | 54 | 7 | 8 | 11 | 15 | 13 | 12 | 61 | 53 | 51 | 41 | |
Total Liabilities | 139 | 153 | 177 | 127 | 117 | 113 | 128 | 144 | 143 | 203 | 210 | 220 | 237 |
44 | 42 | 9 | 9 | 42 | 33 | 33 | 32 | 32 | 30 | 65 | 64 | 64 | |
CWIP | 22 | 43 | 0 | 0 | 0 | 1 | 3 | 20 | 30 | 65 | 3 | 4 | 3 |
Investments | 1 | 0 | 138 | 72 | 49 | 53 | 56 | 53 | 52 | 60 | 71 | 62 | 66 |
72 | 68 | 30 | 46 | 25 | 26 | 35 | 38 | 30 | 47 | 71 | 90 | 104 | |
Total Assets | 139 | 153 | 177 | 127 | 117 | 113 | 128 | 144 | 143 | 203 | 210 | 220 | 237 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2010 | Mar 2011 | Mar 2012 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
12 | 22 | -29 | -8 | 17 | 1 | 1 | 0 | 4 | 46 | 6 | 3 | |
-20 | -24 | 41 | -31 | -20 | -2 | -4 | -14 | -10 | -38 | -15 | 8 | |
7 | 7 | -9 | -0 | 0 | -0 | 6 | 17 | 1 | 2 | 7 | -1 | |
Net Cash Flow | -1 | 6 | 2 | -39 | -2 | -0 | 2 | 3 | -5 | 10 | -2 | 10 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2010 | Mar 2011 | Mar 2012 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 123 | 97 | 51 | 243 | 286 | 196 | 148 | 86 | 109 | 122 | 132 | 142 |
Inventory Days | 46 | 62 | 12 | 124 | 110 | 84 | 39 | 36 | 70 | 35 | 28 | 10 |
Days Payable | 44 | 37 | 19 | 124 | 154 | 184 | 108 | 33 | 89 | 525 | 239 | 200 |
Cash Conversion Cycle | 125 | 121 | 44 | 243 | 241 | 96 | 79 | 89 | 89 | -367 | -79 | -48 |
Working Capital Days | 107 | 19 | -114 | 197 | 237 | 124 | 100 | 79 | 108 | -144 | 25 | 54 |
ROCE % | 15% | 8% | -10% | -9% | 5% | 6% | 1% | 3% | 6% | 10% |
Documents
Announcements
- Closure of Trading Window 2d
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 2d
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 21 Mar
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 18 Mar
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 6 Mar
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Concalls
-
Jun 2023TranscriptPPT
Product Portfolio
The company's product portfolio includes parenteral and nasal products, oral formulations, effervescent tablets & powders, medical devices, nutritional products, cosmetics & herbal products & others. Besides this, it has 400+ products registered across the world. [1] [2]